
EQUIPMENT QUALIFICATION PLAN





Agilent CrossLab Compliance Services

9 E D'BUa Y. ÖÖÙÙÈŒÍÍ ′ÚÛ ′ÜGFHP€

GYfj]WY'HmdY. ÚÛ

7 ca dUbmiBUa Y.

7 i ghca Yf BUa Y#HJhY.

9 E D':] Yb Ua Y. ÖÖÙÙÈEŒÍÍ ´ÚÛ ´ÜŒFHP€È`]

9 E D'Di V']g\ '8 UhY. Ù^] c^{ à^!ÁG ÉÆ€G ÂKÎKÎKHÁŒT

Df]bh8 UhY. $\dot{U}^{\wedge}] e^{A} \{ \dot{a}^{\wedge} | \dot{A}G | \vec{E}G = G | \hat{A} | \dot{K} | H = G \neq G \}$

V^•dÁ¦[*¦æ{Áæ•Á^-∤^&c^åÆ;ÁÔÛÚÆ;±¦^^{ ^}dÈ

HUV`Y'cZ7 cbhYbhg

GYWijcb	DŲ Y
Ù&[]^Áæ)åÁÚˇ¦][•^	н
Öã•[ˇ cã;}Á/^• cÁÖ^• ã } Ás; åÁÜæð; } æþ^	FF
Öã•[ˇ ᾱ[} Á/^•αÂÚ] ^&ãã&æā[}	FG
Ùæ) åælåÁÚ!^] ælææã[}	FG
Øajec\Áxaejañaeaj }	FG
Ú¦^å}ã[}^ÁÛ*æţãã8æqã}}ÆÜÜā;* ^ÁÜæë^	FG
Ú¦^å}ã[}^ÁÛ`æţãã8æqã}}ÆÖ√¸[ÁÚœt^	FÍ
Ô; [•• ŠæàÁÔ[{] ãæ}&^	FJ
FGGG FÌ EÜGFHP€	СН
ÖÒÙÙÁÚÛ KÁÚŒ) åælåÁ/^•ŒÛ ãr^	GJ
Ü^] [¦ơ⁄sæ) åÁÖ^ ãç^¦^ÁU] cất } •	H€
Ù^ ^&c^åÂÛã} æč¦^ÁU] cã;}•	H€
Ô~•{{ ^!ÁŒ] [çæ	HF
Š^* æ Áp[æ&^	HG

GWcdY'UbX'Di fdcgY

Cj Yfj]Yk

 $\hat{O}\hat{U}\hat{A}\hat{U}\hat{O}\hat{O}\hat{A}^c\hat{A$

HÉÔ[}&ãr^kArca); åædåÁ[¦{ædEÁS]}ã&æd|^Ár•^åÁ[¦ÁOE*ā/}dĒ^&[{ { ^}å^åÁÔÛÚ• HÉ/æà`|ædkÁr¢]æ); å^åÁg|{ædEÁS]]ã&æd|^Ár•^åÁ[¦Á8[}æð`¦^ååÁÔÛÚÚ•

Q ÁærÁK[} & ãr^ÁÒÛÚÁæd]]¦[çædÁs[&~{ ^}ơÁ•^åÁq[¦ÁOĽã^^}dÉ^8[{ { ^}å^åÁÔÛÚÚ•ÉÁs@Áx••dÉA^d][ãjo•ÁædàåÁjædæ(^ơ\¦•ÉÁædàåÁqãã•Áçãædæ)]|ã&æà|^DÁæd^Ásãa]|æê^åÁs[Áædæ(} & & ^&Áæàà¦^çãæd°àÁq[;{ ædÁædÁs[;} & ãrÁædà;Áædæ(]}&ãr^Áædà;A;Æædæ() & ãrÁædà;Áædæ() & ãrÁædæ() & ãrÁædæ(

 $= UVOHHAV@&A^8ca[]/\bullet Aca[]/\bullet Aca[]/$

?Ym	Øa¢^åÆrÚŠÔÆr^d][ĝo-‡a[ão•	WPÚŠÔÁ^d[ãơ Ç¦ã æ'Á[å" ^D		Хæі а́ж) &^Áæ [¸^å
HYgh		Ù^d][ã, œ Áæ) åÁÚælæ(^e\ •		Šą̃a•	
ÔÖÙÆ[*[}Æx^¦æ	škaci į }	ÁÞ ÐŒ		Òçãa^}&^Á(. ~~a¢ãã&æaā[}	Án[*[}Á.•^åÁa[Á&[^&c Áåæææ
Ú*{]ÁØ [,Á028&*¦ ÇÚ*{]D	æ&î Áæ;) å ÁÚ!^ &æï á[]}	Ø[, ÁÜæe^ÁFHÁEĒE €€Á, HÐ āj° c^ Ø[, ÁÜæe^ÁGHÁDÈE€€Á, HÐ āj° c^ Ø[, ÁÜæe^ÁGHÁGÈE€€Á, HÐ āj° c^Á Ø[, ÁÜæe^ÁGHÁFĒE€Á, HÐ āj° c^Á		OBS&* 28&^ Ám Ú!^&& đ[} ÁÜ	

I bXYfghUbX]b['h\ Y'HYghGdYW]ZJWUh]cb'GYWl]cb']b'HUVi `Uf'FYj]Yk '8 cWl a Ybhg

Q ÁsaÁsaà`|æiÁÒÛÚÁsa}] | [çæpÁsi[&`{^} dĒs@ Ás^• dĒs^^d] [ā] o• Ása} å Á, æbæ (^c^|• Ēsa) å Áā[ār• Ása^Ás] ā&æl|^ Ásā] |æê^å Ás Ás@ Á[||[¸ā]* |^] |^•^} cænāç^Á[|{ ænE`

Di a d': `ck '5 WW fUWn

Ø[, Æ

	OE; ant cascantACE at^} criscs at A; [} ECE at^} criscs at A; [}				
	Ù^d[åœ	€Ě€	{Š–Qãj	ŠK €ÈF€€	PK ÍÈŒ€
K	Ù^d [ā dK	€ÌÒ€€	{ŠEQāj		
	Šą̃ atK	ŁM	ÍÈŒ€ Ã	ŠK ÍÈŒ€	PK F€È€€

±b^YWf]cb'DfYV[g]cb'5XX]h]cbU': @8

V@ā Á[] cá[} æþÁc∿• cÁsē ÁN} æà|^å Á[¦Ás@ā ÁÖÛÛÈ

OE #\} of(Á [} EOE #\} of(b\&d Á, @o@#OSÖ/#\^ c\&d								
Xão 4/5,^¦ãã 8ac āi}}Ái,^¦-{¦{ ^åÑ	Þ[
Qub/&qaa[}Áx[ˇ{^Áa[}ÁÔ[ˇ{}K	ĺ	řŠ			ŠK	F	PK Í	
Œ^æÁÜÙÖÆĞĄ ãK	ŁM	FÈ€€	Ã		ŠK	FÈ€€	PK ÍÈ € €	
P^at @ÁÜÙÖÆŠāĮ ãiK	ŁM	FÈ€€	Ã		ŠK	FÈ€€	PK ÍÈ € €	

7 c'i a b'HYa dYfUh fY'5 WW fUWn

V @ A (a) å a a a å Á a ^ a e | o Á c • o Á a Á a a a a | ^ å Á ¦ Á c A Á Ô Û Ú È

7 i glca Yf F Ygdcbg]V]`]lj]Yg

V[Á,^\-{\{ÁDEÔÒÁ\$,•d`{^}oÁ`adaā&aæā{}Á^\capa^EA\^`ã^{^}oÁæ••[&aæe^åÁ,ão@\$;•d`{^}oÁ\$[}d[|Áæ)åÁ.•^Á;ÁDEÔÒÁ[-ç,æ-^Á;}Áã^ }^^åÁ{Áo^Á}å^\•d[åÁæ)åÁ•æāæā-að\åÈ

ËÄQQ•d~{^}oÁs{}d[|Ág[Áj∧¦-{|{ Ás@∙Á~adjãa8ææā[} Ás∧•o•È

EXOTÊÒÁ [-ç zet^Ándes& & • - Án † ça & Án * à An * à An

 $\begin{array}{l} \text{CEO}\hat{\Delta} & \hat{\Delta}_{0} & \hat$

CE #^} oÁ^8[{ { ^} å•ÁsææÁs@Á[~ç æ^Á[~c],^[Á•^åÆ] Ás@ÁææÁsææí]}

&*• OÉV@;^-[;^Éæi];|[]; ãææ^Áæ&&^• Ás Ás@Ás• oč { ^} oÁs[} d[|Ás@Æ]• oč { ^} oÆ; &@ÆæÆsææí]}

&*• OÉV@;^-[;^Éæi];|[]; ãææ^Áæ&&^• Ás Ás@Æ]• oč { ^} oÁs[} d[|Ás[-ç æb^ÉA`&@ÆæÆsæé As@Æ* oc { ÁşÔÖÙŒÄ;^^å•Ásææí]} ^

-[;Ás@ÁCE #^} oÁ^];^• ^} cææí; Áæ^-[;^Ás@^Áæ; áç^Á;} Áæ¢ÉæZ]; ÁQEÔÓÁ[-ç æb^Áæ&&^••Á;} Áæ¢ÉQE #^} oÁ^&[{ { ^} å•Ás}•cækæí]} Á; -ÁÞ^ç [;\

OEÔÓÁ[Á[æåÁs@Á|^&&]; å•Ás[} &æÁs@Á|^&&]; ÁgæÁš æáí]} Á; [;\-[, Éæè; åÁ; à]æ@Ás@ÁOÛÜÈ

ËÄÒÛÚÁ^çã\

ËÄÜ^çã^, Ás@ ÁÔÛÚÁ^`]]|a^åÁÇicæ)åæbåÁ;¦Á&[}~ā*`¦^åDÈ

ÊÜ'^``^•ơ&@æ)*^•Á;ÁœÁÔÛÚÆÁ^``ā^åÁQ;Á;^^ơÁ•^¦Á^``ā^{^\okea}Á°`æā*Áæ)*^Á;Á•^DÆ;Áæ}]¦[ç^ÁœÁ`]]|æ°åÁÔÛÚ Ç@ænÁææã~æ•Á•^¦Á^``ā^{^}o□È

EÁOE ; ^^ Áse} å Ás ^ OÁ] ÁS • O ˇ { ^ } OÁS[} O [|Áse&& ^ • Á [Á, ^ ; -[; { Ás@ Á, [; \ ÁG ; [çãs ^ ÁseÁOÖÙÁ[* [} Á; ; Ás@ ÁOÙÒDÈ
EÁOE ; ^^ Áse} å Áse]] ; [ç ^ ÁOEÓÒÁ • æ ª ^ Á; } Ás æ Á Þ ^ ç [; \ ÁOEÓDDÈ
EÁO[; ÁSE[} - ª ˇ ; ^ å ÁOÛÚ • ÊÁ; æði cæði Áse@e) * ^ ÁS[} O [|Áse) å Ás ^ ç æ ā; } Á@e o [; ^ Á; - Ás@ Ás] ^ & & æði æði þ; [ç ^ å ÁOÛÚÈ
EÁÚæ ^ | ´ Ás o [; ^ Áse) å Áse & @ō; ^ Áse) å Áse]] ; [ç ^ å ÁSE]] ^ Aseæ ÁOÛÚÈ
EÁÚæ ^ [Áse] å Ás æ } Áseæ ÁOÛÜÜ, @ } Áse@ Á ˇ æðiæðææði } Á; [; \ Áse ÁSE[{] | ^ cs Áse) å Ás] [; cs å È

5 [] YbhF Ygdcbg]V]]h]Yg

 $\begin{array}{l} CE \ a^{\ } \ o^{\ } \ A^{\ } \ |^{\ } \ e^{\ } \ A^{\ } \ |^{\ } \ e^{\ } \ A^{\ } \ |^{\ } \ e^{\ } \ A^{\ } \ |^{\ } \ e^{\ } \$

ËÄÖ^|ãç^¦Ás@Ásē}]¦[ç^åÁs^\;çæ&^•Áq||[¸ā]*Ás@Ás^•ơÁ;¦[*¦æq;•Ás^•&¦æa^åÁsjÁs@Ásē}]¦[ç^åÅÖÛÚL ËÄÚ¦[çæā^ÁseÁn[&\^åÁse}åÁs'Ēæ]}^åÁÖÛÜÁ][}Ás[{]|^œā}Áş-Ás@Ás^\;çæ&^L ËÄGÁS^``^•ơåĒÄ;¦[çæā^Áse}Ás]æā}}æÁs[\Ēæ]*ÅåÁÖÛÜÁÕÖÁ;Ás@Ásč•d;{^\È

GHUHYa YbhcZ±bhYbh

 $\hat{O} \cdot \text{of} \left\{ \tilde{a} \text{ accept} \right\} \cdot \hat{A} + \hat{A} \cdot \hat{A}$

 $V@\acute{A}^{|c|} = A^{|c|} + A^{|c|} +$

; YbYfU`GHUHYa Ybhg`cb`h\ Y`HYgh]b[`Dfc[fUa

9EDFYj]g]cb'<]glcfm

 $\begin{array}{l} \text{OEOOÁ} \stackrel{`}{\sim} \text{afastaceta}_{\dot{A}}^{\dagger}, & \text{i}_{\dot{A}}^{\dagger}, & \text{i}_{\dot{A}}^{\dagger},$

78 G'GcZtk UfY'DfY!fYei]g]hYg'Zcf'<UfXk UfY'Ei U']Z]WUh]cbg

 $V@\dot{A}[-c; ad^{\dot{A}} \bullet ^a\dot{A}[\dot{A}S[] d[]\dot{A}S \bullet d^{\dot{A}} \bullet ^a\dot{A}[\dot{A}S[] d[]\dot{A}S \bullet d^{\dot{A}} \bullet ^a\dot{A}S \bullet \dot{A}S \bullet \dot$

; `cggUfm

5[] Ybh9ED

ŒÔÒK

 $CE^{\frac{1}{4}} \circ hCE^{\frac{1}{4}} = \frac{h}{h} \circ hCE^{\frac{1}{4}} \circ hCE$

ÖOÙÙÈEGĚÍ′ÚÛ′ÜGFHP€ ÖOÙÙÈEGĚÍ′ÚÛ′ÜGFHP€È~] Úæ*^ÁľÁÐÁHG

Ù^] c^{ à^¦ÁGI ÉÁGEGÍÁÌ KÍ HK€GÁQET

ÒÛÚK

 $\grave{O}^* = \{ \land \} \circ \hat{A} = \hat{A}$

ÒÛÜK

 $\dot{O}^{\tilde{}}$ \ddot{a} { $^{\hat{}}$ \dot{A} $\dot{O}^{\tilde{}}$ $\dot{O}^{\tilde{}}$ \dot{A} $\dot{O}^{\tilde{}}$ $\dot{O}^{\tilde{}}$ \dot{A} $\dot{O}^{\tilde{}}$ $\dot{O}^{\tilde{}}$

ÔÖÙK

Ô • d { ^ | ÁsaææÁ ^ • e^{

Þ^c [¦\ÁŒÔK

OĐÔÒÁNa ÁNg • cæd|^åÁn{} ÁnæÁn^c; [¦\Án[å^Á, ãnó@An Ánó@An Ánæà[¦æne[¦^ÁŠOÐÞÁNg -{æ•d`&c'}^

Š[&#ÁŒÔÒK

OEÔÒÁ^•ãå^•Á;}Áṣà Áṣã å^]^}å^}oÁv¢c^!}æþÁslãç^Á&[}}^&c^åA[}à^@AŠOEÞÁṣ +æ•d°&c°!^

O‡c^¦}æmaç^ÁT^co@|åK

Ùæ) åæ\åÁÖÛÚK

ÒÛÚÁ,¦^Ëå^-ã,^åÁà^ÁOË ã^} oÁs@ædÁs, &|`å^•Áå^-æĕ|oÁs^•œÆ^•¸d [ã,œÆæ) åÁã ãe

Ô[}-at~¦^åAÒÛÚK

ÒÛÚÁs@æÁ@æÁs^^}Á&@æ)*^åÁsæ^åÁj}Á•^¦Á^~~¦Á^~~ã^{ ^} @

Xælãæ) & ^ÊÄÜæ) * ^ K

 $V@Aa)*^{A_{-}}^{A_{-$

Xælåæn) & ^ÉAY K

 \hat{O} @ \hat{A} * \hat{A} (\hat{A} # \hat{A} * \hat{A} # \hat{A} * \hat{A} # \hat{A} * \hat

Xælåæn) & MÉÄUK

Ô@a) *^Áq ÁæÁr^•oÁ, æbæq ^c\hÁc@ædÆn Á; *o ãn ^Ác@ ÁCE ār\}oÁçæbãa; &^Áæ) *^

Xælãæ) &∿ÉÄÖYK

Ö a p Á^] [| c a | * Á a [a a • Á a c c a | Á c c c a h c c e a

Xælæn) & ÉÄÖUK

Ö a þÁ ^] [| cā, * Áā, ão Á, ° o ão ^ Ác@ ÁCE ā^ } oÁ `]] [| c^ å Áæ) * ^

U] a[{} a A/^• dK

CF; A[] ca[} adphada a aa[a] adphan • cho@acc/as A[cha[&] an a Aa[Acc@ Acca) a add a AOÛÛ Ú

Ofååããã{}æ∮ÁÛ^d][ãjdK

Ofāåããã} a aḥÁ; ^æe ˇ ¦^{ ^} oÁṣæ ţ ˇ ^Á[¦ÁæÁs^• oÁ;æææ { ^c^¦Áç-|[Ébē^{] ^ |æe ˇ |^ Ébæ} å Á• [Á; } D

Ei U]Z[WUt]cb @ZY7 mWY GtU[Yg

WÜÙK

ÖÛK

 $\ddot{O}^{\bullet} = \ddot{a} + \dot{A} \dot{O}^{\bullet} = \ddot{a} + \dot{A} \dot{O}^{\bullet} = \ddot{a} + \dot{A} \dot{O}^{\bullet} = \ddot{A} + \dot{A} \dot{A} + \dot$

ŴΚ

UÛK

 $U]^{+}$ area[} $\Rightarrow A\hat{U}^{*}$ area[] $\Rightarrow A\hat{U}^{*}$

ÚÛK

 $\dot{U}^{+} + \{ \{ a \} \& \hat{A} \hat{U}^{*} = a \} \&$

ÜÛK

 $\ddot{U}^{\ } = \frac{1}{2} \frac{1}{4} \frac{1}{4}$

ÚT K

FYZYfYbWY'GcifWYg

OT)VT K

OE, ^ l a8æ) ÁÙ[8æî ĉ Á[lÁ/^•cā] * Áæ) å ÁTæc l ãæd•

ØÖŒK

W}ãc^åÁÛcæc^•ÁØ[[åÁse)åÁÖ¦*ÁŒå{ãjãrdæeã[}

Ռ Úî K

 $\tilde{O}[[\mathring{a}AOE ({æe^\mathring{a}ATæ})^*-æ&c^\mathring{a}*AÚ|æ&c@k^)$

ФUК

Q(c') and A(c') and A(c'

ÒÙUJ€€FK

ÚÔĐÙK

 $\dot{U}@ed{ \ ask^* \ asked} \dot{Q} \bullet] ^8 call{} \dot{A} \dot{Q} [\] ^l assal{} \dot{A} \dot{U} \& @e{ \ } ^n$

WÙÚK

W}ãr^åÁÙæær^•ÁÚ@æd{æ&[]^ãæ

8]ggc`i hjcb'HYgh8 Yg][b'UbX'FUhjcbUY

GHJbXUfX'DfYdUfUfjcb

Ú¦[8^å`¦^kÁÜ^~^¦Á{j kj.\^å}ã[}^Á&^¦cãã&æe^Áj;¦Áå^cæáj•È

:] hYf J U JXUhjcb

Ö^•& [a] a[a] ká v@a ác • o (s; a pa a a ac • ác @ Áa] c \ • Á • ^ a Á[| Á a a [] | ^ ác a a á Á a a a a a á á | | ^] a b ac af } È

DfYXb]gcbYEi U']ZJWUf]cb'!'G]b[`Y'GHU[Y

Ö^•&|a] a] káv@k@{ a&adkar•okar\iaan•ka@kj.r\-{\{ a} &^k/kak@kj.a*•[| a] &r\call kar•[| a] &r\call kar•[| a] &r\call kar\call kar

Ú¦[&^å`¦^kÁÜ^-^¦Áq[Áj¦^å}ãr[}^Á&^¦cãã&æe^Áq[¦Áså^cæá‡•È

DfYXb]gcbY'Ei U']ZJWUh]cb'!'Hk c'GhU[Y

Ö^•&|a] a[} kk/@a k&@{ a&adkv•oko^|aan•ko@k]^|-{|{ ag &^k/a-ko@kaa•[|`a]} kkv•o'|E

Ú¦[&^å`¦^kÁÜ^~^¦Áq[Áj;\^å}ãr[}^Á&^¦cãã&ææ^Áq[¦Áå^cææ‡•È

8 |ggc\i hcb HYghGdYWZWUhcb

8 =GG'\$&'))

\\\\ \angle \ang

GHUbXUfX'DfYdUfUficb

GHUbXUfX'DfYdUfUf]cb%

ÇDEÁ, [¦∖ā)*Án cæ) 忦åÁæ) åÁæÁ&[}d[|Án cæ) 忦åÁæ¦^Á∧``āl^åÁq[Á&æ4&`|ææ^Áà ÁDEa•[¦]cãpãôÁ[¦Án æ&o@Án cæ) 忦åLÁ≦Ánc@Á&`•q[{^\Áå[^•Á, æ}oÁq[&¦^ææ^ÁæÁ&[}d[|Án cæ) 忦åÉÃÃÁDEa•[¦]cãpãôÁæ ÁÞUVÁ&æ4&`|ææ^åÈD

ÁOĘ, æ•Á&@å* ^åÁ[¦Á*]][¦ơåÁ	iãr∙[ˈcā[}Áe^•	v.o^¦•KAOE[]ælæcĕ•KAFA[¦ÁG		
ÃÁOEà•[¦]cãçãcÂS[¸ÁSã(ãtK	NM	IJÈ€	ŠK JJÈ€ F	PK JJÈ€
ÃÁOEà∙[¦]cāçācÁPāt@ÁŠāįādK	ŁM	F€FÈ€	ŠK F€FÈE F	PK F€FÈ€

:]`hYf`JU]XUhjcb

:]`HYf`JU]XUHcb%

	ÁŒĘ, æĉ•Ák&@åˇ ^åÁʦÁŤ]][¦ơåÁsãæ•[ˇŒફ}Áơ•ơ¦•KÁŒṭ]æbæč•KÆFÁ;¦ÁG									
	Ü^&[ç^¦^Æj[,Æjā[ādK	NM	JÌ	Ã	ŠK JÌ	PK JÌ				
С	Ü^&{ç^¦^ÆŠ[¸ÆŠā[ã£K	NM	JJ	Ã						
	Ü^&[ç^¦^ÁPā*@ÁŠā[ãaK	ŁM	F€G	Ã	ŠK F€G	PK F€G				
С	Ü^&[ç^¦^ÁPā*@ÁŠā[ãaK	ŁM	F€F	Ã						

DfYXb]gcbYEi U]ZWUHcb'!'G]b[`Y'GHU[Y

DfYXb]gcbY'Ei U']ZJWUrjcb'!'G]b[`Y'GrU[Y%

Ò æ]•^åÁ/ã ^ÁÙ^d [ā,dK	H€	ו מי.	-^ •	čız	H€	PK H€
		{ ā j ~ (
Õ^[{ ^da&AT ^aa}, Æ, Æ, Æ, æK	NM	ÌF	Ã	SK	ÌF	PK ÌF
Õ^[{ ^da&T ^aa}Æ[, Æã atK	NM	ΪΪ	Ã Ã	Ŏĸ	10	DK 10
Õ^[{ ^da&AT ^aa} ÁP à @ÃSã, ãK	ŁM	JG		SK	JG	PK JG
Õ^[{ ^d a&ÁT ^æ} ÁP ā @ÁŠāį ādK	ŁM	J€	Ã	Ŏĸ	ıñ	DK I Å
Ô[^~a&a^}o4[~Áxæbāææā]}ÁŠā[ātK	ŁM	ΙĒ	Ã	SK	ΙĒ	PK IË
Ô[^~3&3\} ơÁ ~ÁX æð āææā]} ÁŠā] ã K	ŁM	ΙÈ	Ã	Ši ć	o ù r	DI OÈ
Ùœ) åæååÄÖã-^\^} &^ÄŠāĮ ãiK	ŁM	GÈ€	Ã		GÈE	PK GÈ€
V^{] ^ æeč ^ Æ6[, Æ6ā[ãdK	NM	HÎĚ	»Ô		HÎ Ě	PK HÎĚ
V^{] ^ aec ^ ÁP à @ÁSal aik	ŁM	Η̈́Ě	»Ô		Η̈́Ě	PK HÏĚ
Ùæ[] ā]*Á0E8&*¦æ&^ÁŠā[ātK	ŁM	G	Ã	ŠK	G	PK G
ÁCE[] æˈæeˇ • KÁFÁÞ ˇ { à^¦Á; Áç^• • ^ • Áe		•	•	¥		
Ò æ]•^åÁ/ã[^ÂÛ^d] [ā] dK	H€	{ ā j ~ 0			H€ 、	PK H€ 、
Õ^[{ ^da&ÁT^aa}ÁŠ[, ÁŠā[ādK	NM	ÌF	Ã	ŠK	ÌF	PK ÌF
Õ^[{^da&ÁT^aa}ÁŠ[,ÁŠā[ādK	NM	ΪΪ	Ã			
Õ^[{ ^da&ÁT ^æ}ÁPā*@ÆŠāĮãdK	ŁM	JG	Ã	ŠK	JG	PK JG
Õ^[{ ^dã&ÁT^æ}ÁPãT@ÊãĮãdK	ŁM	J€	Ã			
$\hat{O}[\ ^{\sim}-38\hat{a}^{\wedge}\)\ o'_{1}-\dot{A}^{\wedge}\ \text{act}\ \tilde{a}\text{act}_{1}^{2}\)\ \dot{A}\tilde{G}\tilde{a}\ \tilde{a}\text{d}\text{K}$	ŁM	ΙĚ	Ã	ŠK	ΙĚ	PK IĚ
$\hat{O}[\ ^{-}\!$	ŁM	ΙÈΗ	Ã			
Ùœ)åæååÄÖã~^¦^}&^ÆãįãtK	ŁM	Œ	Ã	ŠK	Œ	PK GÈ€
V^{]^¦æc'¦^Æcj,ÆcãjãtK	NM	HÎĚ	»Ô	ŠK	HÎĚ	PK HÎË
V^{]^¦æeč¦^ÁPa*®ÁŠaįãaK	ŁM	Η̈́Ē	»Ô	ŠK	Η̈́Ĕ	PK HÏĚ
Ùæ{] ã;*Á028&*¦æ&^ÁŠã;ãdK	ŁM	G	Ã	ŠK	G	PK G
ÁOE[]ælæe*•KÁFÁÞ*{à^¦Á;^••^ •Áe	^• c^åk ÁW•^	¦ÁÖ^- ∄ ^&	åÁNÙÚÆŠãĮão			
Ò æ]•^åÁ/ã[^ÂÛ^d] [ā dK	H€	{ ā j ~ 0	3,•	ŠK	H€	PK H€
Õ^[{^da&ÁT^aa}ÆĞ[,ÆĞa[aüK	NM	ÌG	Ã	ŠK	ÌG	PK ÌG
Õ^[{^dã&ÁT^aa}Æ[¸Æšã[ãK	NM	ΪÌ	Ã			
Õ^[{ ^da&ÁT^aa}ÁPā*@ÁŠāĮādK	ŁM	JG	Ã	ŠK	JG	PK JG
Õ^[{ ^da&ÁT^aa}ÁPa*@ÊāĮãdK	ŁM	J€	Ã			
$\hat{O}[^{\sim}38\hat{a}^{\sim}]$ $o\hat{A}$ \hat{A} \hat{a} \hat{a} \hat{a} \hat{a} \hat{b} \hat{a} \hat{a} \hat{b}	ŁM	ΙÈ	Ã	ŠK	ΙÈ	PK IÈ
ÖQÙÙÈŒĚÍ′ÚÛ′ÜŒHP€			Úæt^ÁFHÁÐÁHG	Ù^] « {	à^¦ÁGIÉÉ	GeGÍÂIKÍHKE©

С	$\hat{O}[\ ^{\sim}\!$	ŁM	ΙÈG	Ã			
	Ùœa)åædåÁÖã=^¦^}&^ÆããįãnK	ŁM	GÈ€	Ã	ŠK (3È€ [PK QÈ€
	V^{]^ æc' ^ÆG[, ÆGā[ãdK	NM	Η̈́Ē	жÔ	ŠK H	−ÎĚ F	PK HÎĚ
	V^{]^¦æc'¦^ÁPât@ÁŠã[ãdK	ŁM	Η̈́Ē	жÔ	ŠK H	-ijĔĖ F	PK HÏĚ
	Ùæ{] āj*Á0188&*¦æ&^ÁŠāį ãdK	ŁM	G	Ã	ŠK (Э Г	PK G
	ÁŒ[]ælæeĕ•KÁŒÁÞˇ{à^¦Á[Áç^••^ •Ág^•¢	∖åk¶ÂÁV∳^	¦ÁÖ^- ∄ ^.	åÁNÙÚÆĞĄ ão			
	Ò æ]•^åÁ/ã[^ÁÙ^d] [ā] dK	H€	{ ā ř	c ^•	ŠK H	-l € [PK H€
	Õ^[{^dã&ÁT^æ}ÆĞ[,ÆĞã[ãaK	NM	ΙÎ	Ã	ŠK I	Î F	PK IÎ
С	Õ^[{^dã&ÁT^æ}ÁŠ[¸ÁŠãĮãdK	NM	ΙH	Ã			
	Õ^[{^dã&ÁT^æ}ÁPãã@ÁŠãįãaK	ŁM	ĺJ	Ã	ŠK Í	J F	PK ÍJ
С	Õ^[{^dã&ÁT^æ}ÁPãã@ÁŠãįãaK	ŁM	ĺI	Ã			
	$\hat{O}[\ ^{\sim}\!$	ŁM	ÎÈG	Ã	ŠK Î	È E	PKÎÈG
С	$\hat{O}[\ ^{\sim}\!$	ŁM	ΪÈ	Ã			
	Ùœa)åæååÄÖã⊷¦^}&^ÆããįãaK	ŁM	GÈ€	Ã	ŠK (3È€ [PK GÈE
	V^{]^ æc* ^AŠ[, AŠã[ãdK	NM	HÎĚ	жÔ	ŠK H	-ÎĚ F	PK HÎĚ
	V^{]^ aecil^APât@ASaqaak	ŁM	Η̈́Ē	»Ô	ŠK H	-II Ě F	PK HÏĚ
	Ùæ{] āj*Á0188&*¦æ&^ÁŠāį ãdK	ŁM	G	Ã	ŠK (Э Г	PK G
ł	ÁCH]]ælæcĕ•KÁCÁÞ*{à^¦Á;Áç^••^ •Ác^•cº	∖åk¶ÄÁV∳^	¦ÁÖ^-ãj, ^.	åÁNÙÚÆŠąão			
	Ò æ]•^åÁ/ã[^ÁÙ^d] [ā dK	Н€	{ ā j ~	c ^•	ŠK H	-l € [PK H€
	Õ^[{^dã&ÁT^æ}ÆĞ[,ÆĞã[ãaK	NM	ΙÎ	Ã	ŠK I	Î F	PK IÎ
С	Õ^[{^dã&ÁT^æ}ÁŠ[¸ÁŠãĮãdK	NM	ΙH	Ã			
	Õ^[{^dã&ÁT^æ}ÁPā*@ÁŠãįãaK	ŁM	ĺJ	Ã	ŠK Í	J F	PK ÍJ
С	Õ^[{^dã&ÁT^æ}ÁPā*@ÁŠãįãaK	ŁM	ĺΙ	Ã			
	$\hat{O}[\ ^{\sim}\!$	ŁM	ÎÈ	Ã	ŠK Î	È F	PKÎÈF
С	$\hat{O}[\ ^{\sim}\!$	ŁM	ÎÈ	Ã			
	Ùœa)åædåÁÖã=^¦^}&^ÆããįãnK	ŁM	GÈ€	Ã	ŠK (3È€ [PK QÈE
	V^{]^ æc' ^ÆG[, ÆGā[ãdK	NM	Η̈́Ē	жÔ	ŠK H	−ÎĚ F	PK HÎĚ
	V^{]^¦æc'¦^ÁPât@ÁŠã[ãdK	ŁM	Η̈́Ē	жÔ	ŠK H	-ijĔĖ F	PK HÏĚ
	Ùæ{] āj*Á0188&*¦æ&6Á5ājātK	ŁM	G	Ã	ŠK (Э Г	PK G
ł	ÁCH[]ælæcĕ•KACÁÞ*{à^¦Á;Áç^••^ •Ác^•cº	∖å k Á W•^	¦ÁÖ^-ãj, ^.	åÁNÙÚÆŠą̃æ			
	Ò æ]•^åÁ/ā[^ÁÙ^d] [ā] dK	H€	{ ā j ~	Gå	ŠK H	- € [PK H€
	Õ^[{^dã&ÁT^æ},ÁŠ[,ÁŠã[ãdK	NM	ΙÎ	Ã	ŠK I	Î F	PK IÎ
С	Õ^[{^dã&ÁT^æ}ÁŠ[¸ÁŠã[ãdK	NM	ΙH	Ã			
	Õ^[{^dã&ÁT^æ}ÁPã*@ÆŠãĮãdK	ŁM	ĺJ	Ã	šk í	J F	PK ÍJ
	ÖOÙÙÈEŒĬÍ′ÚÛ′ÜGFHP€È`]			Úæ≛^ÁrIÁAÁHG	Ù^] &{ è	à^¦ÁGIÉÁG€GÍ	ÂKÍHK€GÁŒT

С	Õ^[{^da&ÁT^aa)ÁPa*@ÁŠã[ãnK	ŁM	ĺΗ	Ã		
	$\hat{O}[^{\sim}-38a^{\circ}]$ of \hat{A} at \hat{A} at \hat{A} at \hat{A} at \hat{A} at \hat{A}	ŁM	ÎÈ€	Ã	ŠKÎÈ€	PKÎÈ€
С	$\hat{O}[^{\sim}-38a^{\circ}]$ of \hat{A} at \hat{A} at \hat{A} at \hat{A} at \hat{A} at \hat{A}	ŁM	ÎÈ	Ã		
	Ùœ)åæååÄÖã-^\^}&^ÆãįãtK	ŁM	Œ	Ã	ŠK GÈ€	PK ŒŒ
	V^{]^¦æc'¦^ÆSj¸ÆSājādK	NM	ΗÎĚ	жÔ	ŠK HÎĒ	PK HÎĚ
	V^{]^¦æc°¦^ÁPā*@AŠāĮādK	ŁM	Η̈́Ĕ	жÔ	ŠK HÏĒ	PK HÏĚ
	Ùæ{] ā] *Á018& `¦æ& ÁŠā[ãdK	ŁM	G	Ã	ŠK G	PK G

DfYXb]gcbY'Ei U']ZJWUh]cb'!'Hk c'GhU[Y

DfYXb]gcbY'Ei U']ZJWUHjcb'!'Hkc'GHU[Y%

Ò æ}•^åÁVã[^ÁÛ/^d] [ā]dK	H€	{ ā , ĭ (- ^•	ŠK H€	PK H€
Ùœ#^ÁFÁÕ^[{^da&ÁT^æ}ÆĞ[¸ÆĞã[ãdK	NM	ÌΗ	Ã	ŠK ÌH	PK ÌH
Ùcæt^ÁrÁŐ^[{^da&ÁT^æ}ÁŠ[¸ÁŠā[āK	NM	Ì€	Ã		
Ùcæ!*^ÆrÁŐ^[{^dækÁT^æ),Ærê:@Kőĕa[ãnK	ŁM	J€	Ã	ŠK J€	PK J€
Ùcæ!*^ÆrÁŐ^[{^dækÁT^æ),Ærê:@Kőĕa[ãnK	ŁM	ÌΪ	Ã		
Ùcæt^ÁFÁÔ[^~-383à}ơÁ;-ÁXætāænā;}ÁŠā; ãnK	ŁM	HÈ	Ã	ŠK HĒL	PK HÈ
Ùcæt^ÁFÁÔ[^~=888}}ơÁ[-ÁKætāænaā[}Šā[ānK	ŁM	HÈH	Ã		
Ùccet^ÁFÁÙcce)åcelåÁÖã-^¦^}&^ÁŠãįãtK	ŁM	Œ	Ã	ŠK GÈ€	PK GÈ€
Ùcæt^ÁGÁŐ^[{^dã&ÁT^æ}ÁĞ[¸ÁĞã[ãúK	NM	ÌF	Ã	ŠK ÌF	PK ÌF
Ùcæt^ÁGÁŐ^[{^dã&ÁT^æ}ÁĞ[¸ÁĞã[ãúK	NM	ΪΪ	Ã		
Ùcæt^ÁGÁÕ^[{^dã&ÁT^æ)ÁPât@KŠā[ãnK	ŁM	JG	Ã	ŠK JG	PK JG
Ùcæt^ÁGÁÕ^[{^dã8ÁT^æ)ÁPã1@ÁSā[ãnK	ŁM	J€	Ã		
Ùcæt^ÁGÁÔ[^~=888} $)$ ơÁ; $-Á$ Xæbãææðá; $)$ ÁŠã $($ ãðX	ŁM	ΙĚ	Ã	ŠK IĖ	PK IĚ
$\dot{U}_{\text{Cat}} \wedge \dot{A}_{\text{C}} \dot{A}_{\text{C}} \dot{A}_{\text{C}} = \dot{A}_{\text{C}} \dot{A}_{\text{C}$	ŁM	ΙÈ	Ã		
Ùccet^ÁGÁÙcce) åcetåÁÖã-^¦^}&^ÁŠãį ãdK	ŁM	Œ	Ã	ŠK GÈ€	PK GÈ€
V^{] ^ æč ^ ÁŠ[, ÁŠā[ādK	NM	ΗÎĚ	»Ô	ŠK HÎĚ	PK HÎĚ
V^{]^¦æci'^ÁPaï@ÁŠaįãnK	ŁM	Η̈́Ĕ	»Ô	ŠK HÏĒ	PK HÏĚ
Ùæ{] ā]*Á058&°¦æ&°ÁŠā[ādK	ŁM	G	Ã	ŠK G	PK G
ÁCH]]ælæce • KÁFÁÞ { à^¦Á;Áç^••^ •Ág^•c^åKÁ,ÁW•	^¦ÁÖ^-ąji^åÁWÙI	ÚÁŠĄ ão			
Ò æ]•^åÁ/ā[^ÁÙ^d] [ā]dK	H€	{ājřo	3å	ŠK H€	PK H€
Ùœë ^ÁFÁÕ^[{^da&ÁT^æ}ÁS[¸ÁSã[ãK	NM	ÌΗ	Ã	ŠK ÌH	PK ÌH

ÖÓÙÙÈEŒĂÍ ′ÚÛ ′ÜGFHP€È~]

Úæť^ÁFÍÁÐÁHG

Ù^]¢^{à^¦ÁGIÊĞG€ĞİÂİKİHK€ĞÁQET

ÖOÙÙÈEŒĂÍ′ÚÛ′ÜGFHP€ÈЎ]

С	Ùœt^ÁFÁÕ^[{^dætÁT^æ}ÆS[¸ÆSā[æK	NM	Ì€	Ã		
	Ùœt^ÁrÁŐ^[{^dæÁr^æ)ÁPã@ÁSã,ãK	ŁΜ	J€	Ã	ŠK J€	PK J€
С	Ùœt^ÁrÁŐ^[{^dæÁr^æ)ÁPã@ÁSã,ãK	ŁΜ	ÌΪ	Ã		
	Ùœt^ÁFÁÔ[^~aBan}of\-ÁXætaaeaa}}ÁSā añK	ŁΜ	HÈ	Ã	ŠK HĒL	PK HÈ
С	Ùœt^ÁFÁÔ[^~aBaN}oÁ;-ÁXætäædā]ÁŠā[āfK	ŁM	HÈH	Ã		
	Ùœt^ÁFÁÙœ)åæååÁÖã-^¦^}&^ÆãįãtK	ŁΜ	Œ	Ã	ŠK CHÈ€	PK GÈ€
	Ùœ≛^ÁGÁÕ^[{^dæAT^æ)ÁŠ[¸ÁŠā[ãnK	NM	ÌF	Ã	ŠK ÌF	PK ÌF
С	Ùœ≛^ÁGÁÕ^[{^dækÁT^æ}ÁŠ[¸ÁŠā[ādK	NM	ΪΪ	Ã		
	Ùœ≛^ÁGÁÕ^[{^dækÁT^æ)ÁP宯ŠāĮãdK	ŁΜ	JG	Ã	ŠK JG	PK JG
С	Ùœ≛^ÁGÁÕ^[{^dækÁT^æ}ÁPå®ÁSa[aiK	ŁM	J€	Ã		
	Ùœ 4 GÁÔ[2 Bã 3] o 4 Axæ 4 Bã 4] ÁŠãĮ ãnK	ŁM	ΙÈ	Ã	ŠK IÈ	PK IÈ
С	Ùœ *^ÁGÁÔ[^~-3821}o ¼-ÁXæ ãæ aã}}Ãã jãK	ŁΜ	ΙÈΗ	Ã		
	Ùœt^ÁGÁÛœ)åæåÁÖã-^¦^}&^ÁŠãĮãtK	ŁM	Œ	Ã	šk GÈ€	PK ŒŒ
	V^{]^¦æč¦^ÁŠ[,ÁŠā[ãdK	NM	ΗÎĚ	»Ô	ŠK HÎĒ	PK HÎĚ
	V^{]^¦æĕ¦^ÁPãt@ÁŠãĮãŭK	ŁΜ	Η̈́Ē	»Ô	ŠK HIĖ	PK HÏĚ
	Ùæ{] āj*ÁO58&°¦æ&°ÁŠāĮãdK	ŁM	G	Ã	ŠK G	PK G
	ÁQ[]ælæe • KÁFÁÞ*{ à^¦Á;Áç^••^ •Áe^• c^å KÁ;ÁN•^¦ÁÖ^-	ą̃ ^åÁWÙĹ	JÁŠãį ão			
	Ò æ}•^åÁVã(^ÁÛ^d][ãjdK	H€	{ ā , ĭ	g^•	ŠK H€	PK H€
	Ùœ≛^ÁFÁÕ^[{^dā&ÁT^aa}ÁŠ[¸ÁŠã[ãdK	NM	ÌΗ	Ã	ŠK ÌH	PK ÌH
С	Ùœ#^ÁFÁŐ^[{^d&AT^a),ÁS[,ÁSã[ãdK	NM	Ì€	Ã		
	Ùœ≛^ÁFÁÕ^[{^dãbÁT^æ}ÁPã®ÁSã,ãnK	ŁM	J€	Ã	ŠK J€	PK J€
С	Ùœ≛^ÁFÁÕ^[{^dãsÁT^æ}ÁPã®ÁSã;ãnK	ŁΜ	ÌΪ	Ã		
	Ùœ 4 ÁFÁÔ[^~&8& 3 } 4 (4 Xæ 4 8æ 4 } ÁŠã[ãtK	ŁΜ	HÈ	Ã	ŠK HĒL	PK HÈ
С	Ùœ 4 ÁFÁÔ[^~&8& 3 } 4 (4 Xæ 4 8æ 4 } ÁŠã[ãtK	ŁΜ	HÈH	Ã		
	Ùœt^ÁFÁÙœ)åæåáЮã~^¦^}&^ÆãąãK	ŁΜ	Œ	Ã	šk Œ	PK ŒE
	Ùœ*^ÁGÃÕ^[{^dã&ÁT^æ}ÆĞ[,ÆĞã[ãdK	NM	ÌG	Ã	ŠK ÌG	PK ÌG
С	Ùœ≛^ÁGÁÕ^[{^dãkÁT^æ}ÁSj¸ÁSãjãnK	NM	ΪÌ	Ã		
	Ùœ≛^ÁGÁÕ^[{^dãsÁT^æ}ÁPã®ÁSã;ãnK	ŁΜ	JG	Ã	ŠK JG	PK JG
С	Ùœe*^ÁGÁÖ^[{^dãsÁT^æ}ÁPã®ÁSã;ãnK	ŁΜ	J€	Ã		
	Ùæt^ÁGÁÔ[^~=88ã\}oÁ; $-Á$ Xætäææāj $\}ÁŠã[ãfX$	ŁM	ΙÈΗ	Ã	ŠKIÈH	PK I ÈH
С	$\dot{U}_{coet}^* \wedge \dot{AG} \dot{O}_{coet}^* \sim 386) \circ \dot{A}_{coet}^* + \dot{A}_{coet}^* = 366$	ŁM	ΙÈG	Ã		
	Ùœt^ÁGÁÚœn) åætåÁÖã-^¦^}&^Æãąí ãtK	ŁM	Œ	Ã	šk c£ne	PK Œ
	V^{]^¦æč¦^ÁŠ[,ÁŠā[ādK	NM	HÎĚ	»Ô	ŠK HÎĒ	PK HÎĚ
	V^{]^¦æci'^ÁPãt@ÁŠãįãdK	ŁM	Η̈́Ē	»Ô	ŠK HIĖ	PK HÏĚ
Ö	OÒÙÙÈEGĚÍ′ÚÛ′ÜGFHP€	Úæ*	^ÁFÎÁÐÁH	G	Ù^]¢^{à^¦ÁGIÉĞG€	GÍÂIKÍHK€GÁŒT

	Ùæ[] ā]*Á01888°¦æ88°Æšā[ãnK	ŁM	G	Ã	ŠK G	PK G
ł	ÁCH;]ælæe*•KÁCÁÞ~{à^\Á;^••^ •Áe\•c^åKÂÁV•^	¦ÁÖ^-ãj,^åÁWÙl	ÚÁŠã, ão			
	Ò æ]•^åÁVą ^ÁÙ^d][ā]dK	H€	{ ā j ~	c ^•	ŠK H€	PK H€
	Ùœe*^ÁrÁŐ^[{^dāsÁr^æ)Áő[,Áőā[ãnK	NM	ΙÌ	Ã	šk lì	PK IÌ
С	Ùœe*^ÁrÁÕ^[{^da&Ár^aa}ÁŠ[,ÁŠā[āaK	NM	ΙÍ	Ã		
	Ùcæt^ÁrÁŐ^[{^dākÁT^æ)ÁPāt@ÁSā;ādK	ŁM	ÍΪ	Ã	šk íï	PK ÍÏ
С	Ùcæt^ÁrÁŐ^[{^dākÁT^æ)ÁPāt@ÁSā;ādK	ŁM	ÍG	Ã		
	$\dot{U}_{\text{CRE}} \wedge \dot{A} F \dot{A} \hat{O} [\wedge \sim 38.21 \setminus O \hat{A} + \dot{A} K \approx 38.21 \setminus \dot{A} \tilde{S} \hat{a} = 38.21 \times \dot{A} \hat{S} \hat{A} \hat{A} \hat{A} \hat{A} \hat{A} \hat{A} \hat$	ŁM	ΙĒ	Ã	ŠK IĒ	PK IË
С	Ùœet^ÁFÁÔ[^~=3821\}ơÁ;-ÁXæbāææā[}ÁŠā[ā6K	ŁM	ÍÈH	Ã		
	Ùœet^ÁFÁÙœe)åæååÄÖã-^\^}&^Æãa[añK	ŁM	Œ	Ã	ŠK CHÈ€	PK ŒŒ
	Ùœ#^ÁGÁŐ^[{^dā&ÁT^æ)}ÁŠ[,ÁŠā[ādK	NM	ΙÎ	Ã	ŠK IÎ	PK IÎ
С	Ùœ#^ÁGÁŐ^[{^dā&ÁT^æ)ÁŠ[,ÁŠā[ãaK	NM	ΙH	Ã		
	Ùcæ#^ÁGÁŐ^[{^dā&ÁT^æ)ÁPā*@ÁŠā;ãaK	ŁM	ĺJ	Ã	ŠK ÍJ	PK ÍJ
С	Ùœ#^ÁGÁŐ^[{^da&ÁT^aa}ÁPa*@ÁSa;ãaK	ŁM	ĺI	Ã		
	$\dot{U}_{\text{CR2}} \wedge \dot{A}_{\text{C}} \dot{Q} \dot{Q} [\wedge \sim 38.8^{\circ}) \text{ of} (\dot{A}_{\text{CR2}} \dot{A}_{\text{RR2}} \dot{A}_{\text{RR2}}) \dot{A}_{\text{C}} \dot{A}$	ŁM	ÎÈ	Ã	ŠK ÎÈĒ	PK ÎÈ
С	$\dot{U}_{\text{CRE}} \wedge \dot{A}_{\text{CRE}} \dot{Q}_{\text{CRE}} \wedge \dot{A}_{\text{CRE}} \dot{Q}_{\text{CRE}} \wedge \dot{A}_{\text{CRE}} \dot{Q}_{\text{CRE}} \dot{Q}_{$	ŁM	ΪÈ	Ã		
	Ùœet^ÁGÁÚœe) åætåÁÖã-^\^}&^ÁSã[ãtK	ŁM	Œ	Ã	ŠK CHÈ€	PK GÈ€
	V^{] ^ æc	NM	ΗÎĚ	»Ô	ŠK HÎĚ	PK HÎĚ
	V^{]^¦æc'¦^ÁPâ'@KŠã[ãnK	ŁM	Η̈́Ē	»Ô	ŠK HÏĒ	PK HÏĚ
	Ùæ[] ā]*Á028&*¦æ&?Á5ã[ãnK	ŁM	G	Ã	ŠK G	PK G
ł	ÁCH;]ælæe*•KÁCÁÞ~{à^\Á;^••^ •Á¢^•¢°åKÁ ÁV•^	¦ÁÖ^-ąj̃, ^åÁVÙl	ÚÁŠãĮ ão			
	Ò æ]•^åÁVã; ^ÁÙ^d][ã;dK	H€	{ ā ř	Gå	ŠK H€	PK H€
	Ùœe*^ÁrÁŐ^[{^dāsÁr^æ)Áő[,Áőā[ãnK	NM	ΙÌ	Ã	šk lì	PK IÌ
С	Ùœe*^ÁrÁŐ^[{^dāsÁr^æ)Áő[,Áőā[ãnK	NM	ΙÍ	Ã		
	Ùœet^ÁrÁÕ^[{^dāsÁr^æ)Árāt@Ásā;ānK	ŁM	ÍΪ	Ã	šk íï	PK ÍÏ
С	Ùœe*^ÁrÁŐ^[{^dākÁr^æ}Ár?å*@ÁSã;ãnK	ŁM	ĺF	Ã		
	$\dot{\mathbf{V}}_{\text{COS}}^{\dagger} \wedge \dot{\mathbf{A}}_{\mathbf{F}}^{\dagger} \dot{\mathbf{O}}_{\mathbf{F}}^{\dagger} \wedge \mathbf{A}_{\mathbf{S}}^{\dagger} \dot{\mathbf{A}}_{\mathbf{F}}^{\dagger} \dot{\mathbf{A}}_$	ŁM	ΙĒ	Ã	ŠK IĒ	PK IË
С	Ùœet^ÁFÁÔ[^~=8&81\}ơÁ;-ÁXæbēanenāj}ÁŠājānK	ŁM	ĺĦ	Ã		
	Ùœt^ÁFÁÙœ)åæååÖã-^\^}&^Æãa[ãnK	ŁM	Œ	Ã	ŠK GÈ€	PK Œ
	Ùcæt^ÁGÁŐ^[{^dā&ÁT^æ},ÁS[,ÁSā[ādK	NM	ΙÎ	Ã	ŠK IÎ	PK IÎ
С	Ùœ#^ÁGÁŐ^[{^dā&ÁT^æ}ÁĞ[,ÁĞā[āaK	NM	ΙH	Ã		
	Ùcæ*^ÁGÁŐ^[{^dā&ÁT^æ}ÁPā*@ÁŠā;ādK	ŁM	ĺJ	Ã	ŠK ÍJ	PK ÍJ
С	Ùcæt^ÁGÁÕ^[{^dā&ÁT^æ}ÁPāt@ÁŠāĮādK	ŁM	ĺI	Ã		
	$\dot{U}_{\text{cat}} \wedge \dot{A}_{\text{cat}} = \dot{A}_{\text{cat}} \wedge \dot{A}_{\text{cat}} = \dot{A}_{\text{cat}} \wedge \dot{A}_{\text{cat}} = \dot{A}_{\text{cat}} \wedge \dot{A}_{\text{cat}} = \dot{A}_{\text{cat}} + \dot{A}_{\text{cat}} + \dot{A}_{\text{cat}} + \dot{A}_{\text{cat}} = \dot{A}_{\text{cat}} + \dot{A}_{\text{cat}} + \dot{A}_{\text{cat}} + \dot{A}_{\text{cat}$	ŁM	ÎÈ€	Ã	ŠK ÎÈ€	PKÎÈ€
	ÖQÙÙÈEGĚÍ′ÚÛ′ÜGFHP€ ÖQÙÙÈEGĚÍ′ÚÛ′ÜGFHP€À~]	Úæŧ	^ÁrïÁÐÁH	G	Ù^]c^{à^¦ÁGIÉÁG€	GÍÂIKÍHÆGÁŒT

С	Ùœt^ÁGÁÔ[^~=3831}oÁ;-ÁXætánezá]}ÁŠá[ánK	ŁM	ÎÈ	Ã		
	Ùœt^ÁGÁÚœa) åætåÁÖã-^¦^}&^ÁŠãĮãtK	ŁM	Œ	Ã	ŠK GÈ€	PK GÈ€
	V^{]^læcil^ÁS[,ÁSā[ādK	NM	HÎĚ	жÔ	ŠK HÎĒ	PK HÎĚ
	V^{]^¦æcč¦^ÁPāt@AŠāįãnK	ŁM	Η̈́Ē	»Ô	ŠK HÏĚ	PK HÏĚ
	Ùæ{] āj*ÁOB&&°¦æ&^ÁŠā[ãdK	ŁM	G	Ã	ŠK G	PK G
ł	ÁCE[]ælæce•kÁCÁÞ*{à^¦Á;^••^ •Ác^•c^åkÁ;ÁV•^¦ÁÖ^-	ą̃^åÁWÙĹ	JÁŠĄ ão			
	Ò æ}•^åÁ/ā; ^ÁÙ^d][ā;dK	H€	{ ā j ~ 0	^•	ŠK H€	PK H€
	Ùœe*^ÁFÁŐ^[{^dã&ÁT^æ},ÁŠ[,ÁŠã[ãtK	NM	ΙÌ	Ã	ŠK IÌ	PK IÌ
С	Ùœ*^ÁFÁÕ^[{^dã&ÁT^æ}ÁŠ[,ÁŠã[ãfK	NM	ΙÍ	Ã		
	Ùœe*^ÁFÁŐ^[{^dãbÁT^æ}ÁPã®ÁŠãĮãnK	ŁM	ÍΪ	Ã	ŠK ÍÏ	PK ÍÏ
С	Ùœe*^ÁFÁŐ^[{^dãbÁT^æ}ÁPã®ÁŠãĮãnK	ŁM	ĺF	Ã		
	Ùœt^ÁFÁÔ[^~a&a^}oÁ; $-Á$ Xætäææāj $\}$ ÁŠāį āiK	ŁM	ΙË	Ã	ŠK IĒ	PK IË
С	Ùœt^ÁFÁÔ[^~~3831}ơÁ;-ÁXætäænañ;}ÁŠã[ãnK	ŁM	ĺĦ	Ã		
	Ùæt^ÁFÁÚæ) åætåÁÖã-^¦^}&^Æã(ãtK	ŁM	Œ	Ã	ŠK GÈE	PK GÈ€
	Ùœ*^ÁGÃÕ^[{^dã&T^æ}ÆĞ[,ÆĞã[ãdK	NM	ΙÎ	Ã	ŠK IÎ	PK IÎ
С	Ùœe*^ÁGÁÖ^[{^dã&ÁT^æ},ÁĞ[,ÁĞā[ãdK	NM	ΙH	Ã		
	Ùœe*^ÁGÁŐ^[{^dãsÁT^æ}ÁPã®ÁSã;ãnK	ŁM	ĺJ	Ã	ŠK ÍJ	PK ÍJ
С	Ùcæ*^ÁGÁŐ^[{^dãkÁT^æ}ÁPã®ÁSã;ãnK	ŁM	ĺΗ	Ã		
	Ùœ * ^ÁGÁÔ[^~=3821*} oÁ; -ÁXæ ãæ aã;} ÁŠã; ãdK	ŁM	ÍÈ	Ã	ŠK ÍÐ	PK ÍÐ
С	$\dot{U}_{coet}^{a} \wedge \dot{A}_{coe}^{a} \hat{A}_{coe}^{c} \hat{A}_{coe}^{c} \hat{A}_{coe}^{e} \hat$	ŁM	ÎÈ	Ã		
	Ùœt^ÁGÁÚœ) åætåÁÖã-^¦^}&^Æãį ãtK	ŁM	Œ	Ã	ŠK GÈ€	PK ŒŒ
	V^{]^ aecil^A5j, A5ajaiK	NM	HÎĚ	»Ô	ŠK HÎĒ	PK HÎĚ
	V^{]^¦æeč¦^ÁPā*@AŠāįãnK	ŁM	Η̈́Ē	»Ô	ŠK HÏĒ	PK HÏĚ
	Ùæ{] āj*Á078&%; æ&6.Êā[ãdK	ŁM	G	Ã	ŠK G	PK G

HOW AGILENT CROSSLAB COMPLIANCE SERVICES INTEGRATE WITH QUALITY SYSTEMS AND REGULATIONS Agilent CrossLab Compliance Services






Agilent CrossLab Compliance Services

Agilent CrossLab Compliance Services are designed to seamlessly integrate with traditional quality systems used by firms and recognized by regulatory agencies worldwide. Analytical instruments must be suitable for their intended use. This requirement is good science in all laboratories and a regulatory requirement in pharma and biopharma laboratories. A life-cycle process for documenting and testing the suitability of laboratory instruments should be followed and Agilent recommends the life cycle framework defined in USP General Chapter <1058> on Analytical Instrument Qualification (AIQ). USP <1058> defines the governing framework and requirements that need to be satisfied, but the laboratory is responsible for how they satisfy these requirements.

- The United States Pharmacopoeia (USP) is the only major pharmacopeia with a general chapter dedicated to analytical
 instrument qualification, making <1058> an important global regulatory reference. The information is provided in a
 scientific, risk-based approach to analytical instrument qualification (AIQ). However, the life-cycle framework contained
 within USP <1058> is not prescriptive in its implementation, making the embedded scientific and risk-based principles
 flexible and universally applicable.
- The scientific process followed by CrossLab uses the Agilent's Automated Compliance Engine (ACE) to deliver paperless
 electronic qualification. The life-cycle stages Agilent perform are highlighted in the life-cycle diagram below. As part of
 this life-cycle, Agilent can configure the qualification tests performed to align with user requirements.



USP <1058> AIQ Framework

NOTE: RQ services, described later in this document, can be added to standard qualification services.

ACE Workflow and Equipment Qualification Plans (EQPs)

Overview

Within the ACE workflow, the qualification tests, setpoints, and limits are defined in an EQP that can be configured to ensure that testing satisfies user requirements. When the qualification work is complete, an Equipment Qualification Report (EQR) is issued. The electronic workflow used within ACE has significant data integrity advantages over traditional paper or Excel-based qualification protocols, as validated calculations can be performed directly using electronic data such as chromatograms and metrology test values. Several of the instrument life-cycle stages are the responsibility of the laboratory, Agilent can provide compliance consultancy services and documentation which can help customers satisfy these requirements. These additional services are not included in our typical qualification offering.



High-level ACE Qualification Workflow

Standard and User-defined Limits

(Hardware qualifications only)

EQPs are available for download and approval as standard documents with Agilent recommended tests, setpoints, and limits, or they can be electronically configured by approved personnel to align with user requirements and intended range of use requirements. The degree of configuration depends on the analytical technology, but most EQPs can be configured to some degree, and one feature that can typically be changed is test limits.

EQPs are designed to be configurable (dependent on the analytical technology and standard requirements), but including additional tests or setpoints can impact the qualification time and associated cost. If a test limit is changed, ACE includes the capability to report results against the Agilent approved limit and any customer required limits (that is, both can be reported simultaneously).

If a user-defined test limit is more stringent than an Agilent recommended limit, Agilent makes no guarantee or obligation regarding the instrument passing the tighter test specification requirements. It is important to appreciate that tests performed under conditions of use (that is, to satisfy pharmaceutical monograph and application requirements) can have different limits than those defined in the OQ. It is the continuum of the combined OQ, PQ, and any point of use testing performed each time the instrument is used that together satisfy regulatory requirements.

User Requirements Specification (URS)

The purpose of user requirements is to document the intended use of the instrument within the life-cycle process and quality management system (QMS) being followed. Therefore, the URS is a customer / laboratory responsibility. Defining user requirements is often used to guide the customer in instrument selection and is stated as the first activity that should be followed in <1058>. The URS is important for two main reasons.

- It is a regulatory requirement for FDA and EU GMP that the intended use of the instrument and any software must be specified.
- Investment protection perspective means getting the right instrument for the right job.

Qualification protocols should test the instrument against any limits or specifications listed in the URS, which should document the intended range of use. Depending on the instrument complexity and how it is classified, a separate URS document may not be needed, but the URS requirements of the <1058> framework must be satisfied. A separate URS is almost always recommended for computerized systems.

An instrument performance specification is a product of the instrument development process by the supplier. It typically documents the performance the instrument can achieve. The URS should be based on intended use of the instrument and not the instrument specification. Additionally, if the intended use of a system changes, this may trigger a need to review the URS and associated qualification testing (for example, to ensure range of use is tested if used with a new analytical procedure).

Agilent offers compliance consultation services and documentation that can help customers address URS requirements.

Design Qualification (DQ)

The main function of the DQ stage of the laboratory instrument life-cycle process is to document why the selected instrument is suitable. Typically, this includes consideration of the instrument specification, how the instrument will be qualified, and the QMS followed by the instrument manufacturer. All together, these confirm that instrument performance is capable of satisfying user requirements. Depending on laboratory instrument life-cycle policy or SOPs being followed, instrument requirements and the relationship between the URS and DQ stages may vary – but as long as the <1058> framework principles are satisfied, this is not a problem, as it is left to each laboratory to justify and document its specific approaches.

The responsibility for satisfying DQ requirements primarily lies with the laboratory, with support from the supplier.

Agilent's approach to satisfying DQ requirements of USP <1058> includes the following.

- All Agilent hardware and software laboratory products, including the ACE software used to deliver qualification services, are designed, manufactured, and tested according to Agilent internal quality life-cycle development procedures.
- Certificates of Agilent testing, validation, and conformance to standards are provided with new Agilent instruments and similar certification can be provided for ACE software.
- Agilent is capable of installation, support, preventive maintenance, on-going qualification, and re-qualification after repair and user training worldwide.

Agilent offers a compliance consultation service that can help customers with DQ documentation.

Installation Qualification (IQ)

The main functions of the IQ stage are to document that laboratory is suitable (for example, critical systems typically include a site inspection / checklist), that the instrument is installed correctly in the environment, and IQ checks such as module start up are completed. IQ is provided and automated by ACE, which collects, checks, and tests Agilent hardware and software products for the following.

- 1. Purchase Order Details: Allows the customer to verify that the instrument being qualified matches their design requirements (if available) and purchase order.
- 2. Preparation and Installation Details: Gathers and records information about preparation and installation documents.
- 3. Documentation: Gathers and records information about reference and user manuals for initial installations.
- Product Quality Assurance Details: Collects and records certificates and other forms that verify that the vendor has developed and built the product according to internal standards.
- 5. Startup: Verifies that all modules/components start up properly.
- 6. Installation Verification (software only): Verifies the correctness of all installation-related files.

Operational Qualification (0Q)

The main function of the OQ stage is to evaluate and document instrument performance at the intended operational range of use. OQ protocols should include a mix of metrology, functional, and operational tests. ACE qualification protocols include information about the test description and rational, setpoints, and the limits (acceptance criteria) for each technique, category, and instrument configuration.

OQ is provided and automated by ACE. ACE checks and tests for Agilent hardware and software products include the following.

- Metrological tests such as flow, temperature, pressure, and so on that ensure that the system is performing within Agilent (or user) specifications.
- Qualification results are reported in the EQR, which can include details of all test certificates, standards, and training
 information for the engineer performing the work. (Note that the EQR can be configured to customer requirements.)
- · System or "holistic" tests verify the combined functions of the various system components
- The qualification testing can be configured to ensure URS requirements, such as range of use are tested.

For software qualification, the OQ consists of automated diagnostics regression testing and verification of the software installation. This supports continued use of the software in regulated environments (at install and as part of supporting periodic review).

In line with regulatory requirements, the EQPs should be approved before work is performed and the EQR should be reviewed and approved when the work is complete (as illustrated in Figure 2). The EQR contains all the raw data, results, and relevant information and attachments for complete compliance and traceability.

Mechanical Qualification (MQ)

(Dissolution systems only)

The main function of the MQ stage is to document that the mechanical performance of the instrument meets specifications and is functioning properly.

Performance Qualification (PQ)

The main function of the PQ stage is to document that the instrument is fit for purpose under conditions of intended use and to create an approved framework that ensures the instrument continues to perform as required. Because instrument range of use is tested within the 0Q stage, it is usually not necessary to test this during PQ. It should be noted that requirements for instrument maintenance and repair fall within the PQ life cycle stage within the

The customer is responsible for satisfying PQ requirements. (NOTE: Agilent can provide a PQ for Dissolution systems only.)

It is important to note that PQ is a lifecycle activity and not a one-time event. PQ tests may include activities such as method validation or system suitability tests (SST), but in Agilent's opinion, SSTs contribute towards ensuring continued performance of the instrument (that is, PQ testing), but do may not fully satisfy <1058>PQ requirements.

Repair Qualification (RQ)

After an instrument is repaired, tests should be performed to evaluate the effectiveness of the repair and document that repaired instrument satisfies performance requirements. Agilent offers a service called Repair Qualification (RQ), which refers to the requalification of laboratory instrument hardware after a repair. For some laboratory systems, to document the performance after repair may require a full OQ. However, for some modular or component-based systems, such as HPLC and GC for example, partial qualification testing can be justified. This is accomplished by performing the qualification tests that are applicable to only the module or system component related to the repair, reducing the time the instrument is out of service. Requalifying the instrument after repair is a regulatory requirement defined in USP <1058>.

Agilent offers service contracts to repair and requalify an instrument during the period between scheduled annual OQs.

The level of retesting is prescribed in the RQ section of ACE: a form is displayed for the operator showing all types of repairs possible and the retesting required. Part of an example form for an LC system is shown below.

Re-Qualification After Repair		
Pump Strategies		
Repair/Replace Strategy	Modules	00 Testing
Internal pump head parts, active inlet valve (or AIV cartridge), (parts of) check valves, reference valves, inlet manifold or pump drive, or taking pump head apart to clean (versus repair)	Any pump	Flow Accuracy & Precision
Pulse damper, pressure transducer	Any pump	Flow Accuracy & Precision
Multi-channel gradient valve	Quaternary	Flow Accuracy & Precision Gradient Composition

The full list of RQ repair and retest guidance is available for customer review.

www.agilent.com/chem/qualification

Information, descriptions and specifications in this publication are subject to change without notice.

© Agilent Technologies, Inc. 2024 Published in USA



DISSOLUTION PERFORMANCE VERIFICATION STANDARD - PREDNISONE

(10 mg nominal prednisone content per tablet)

USP Catalog No.: 1222818 USP Lot No.: R213H0

Valid Use Date	30-SEP-2026
Storage/Handling As per the label.	
Uses General Chapter <711> Dissolution, Performance Verification Test (PVT), Apparatus 2	

Dissolution <711>

Medium: 499 g of degassed purified water maintained at 37° ± 0.5°

Medium degassing: Recommended degassing procedure: Heat a suitable amount of water, while stirring

gently to about 41-45°. Filter under vacuum through a 0.45- μ m-porosity filter into a suitable filtering flask equipped with a stirring device. Seal the flask and continue to apply vacuum while stirring for an additional five minutes. Measured vacuum should be

less than 100 mbar.

Note: Other validated degassing methods that reduce the total dissolved gas in the

media can also be used.

Apparatus: Apparatus 1 (Basket) or Apparatus 2 (Paddle) at 50 RPM

Note: If equipment is dedicated for use with only one apparatus (basket or paddle),

then performance verification is only required for that apparatus.

Time: 30 minutes

Standard solution: A known concentration of USP Prednisone RS in Medium.

Note: An amount of methanol or ethanol not to exceed 5% of the total volume of the standard solution may be used to bring the prednisone reference standard into

solution.

Sample solution: Laboratory can choose either Single-Stage Test or Optional Two-Stage Test scheme to

obtain Sample Solutions.

A filtered portion of the solution under test, suitably diluted, if necessary, with Medium

to obtain a concentration similar to that of the Standard solution.

Note 1: The filtering method must not cause adsorptive loss of drug (using 0.45-μm

PVDF material or equivalent).

Note 2: Bias introduced by automated methods is to be avoided.

Analysis: UV at 242 nm

Copyright 2024 The United States Pharmacopeial Convention. All rights reserved. USP Reference Standard Certificate Template No.: FORM-00008-03

Page 1 of 6



Dissolution <711>

Procedure: Determine the quantity of prednisone, C₂₁H₂₆O₅, dissolved at 30 minutes in each vessel

expressed as percent of the labeled amount.

Single-Stage Test Instructions and Acceptance Criteria

For each position in the assembly, test one USP Dissolution Performance Verification Standard –
Prednisone (DPVS – Prednisone) RS tablet, and record the percent dissolved at the sampling time point
specified. Transform the percent dissolved results to the natural log scale, determine the mean and
variance. For assemblies with 12 or 14 dissolution vessels, no further testing is required.

- 2. For assemblies with fewer than 12 positions, repeat Step 1 with an additional set of tablets. Transform the percent dissolved results to the natural log scale, determine the mean and variance.
- 3. Calculate the average of the two means and of the two variances obtained in Steps 1 and 2.

 Use the results from Step 1 alone for assemblies that have 12 or 14 positions.
- 4. Convert the results of Step 3 to a geometric mean (GM) and percent coefficient of variation (%CV). See Calculation Example for details.
- 5. Compare the results of Step 4 to the Single-Stage acceptance criteria in Table 1. The GM must not fall outside the limits, and the %CV must not be greater than the limit. If both meet the criteria, the assembly has passed the PVT.

Table 1. Performance Verification Test Acceptance Criteria for Single-Stage Test

Apparatus	No. of vessels per run	Geometric Mean, % Prednisone Dissolved	%CV
1 (Basket)	6	77-90	4.4
	7	77-90	4.3
	8	78-90	4.2
	12	77-90	4.3
	14	77-90	4.2
2 (Paddle)	6	43-54	7.1
	7	43-54	6.9
	8	43-53	6.8
	12	43-54	7.0
	14	43-54	6.9

Copyright 2024 The United States Pharmacopeial Convention. All rights reserved. USP Reference Standard Certificate Template No.: FORM-00008-03

Page 2 of 6

ÖQÙÙÈEGĂÍ′ÚÛ′ÜGFHP€È`]



Optional Two-Stage Test Instructions and Acceptance Criteria

A laboratory may choose to implement the PVT as a Two-Stage test in case of assemblies with less than 12 positions. The Two-Stage test is a statistically valid means of allowing the possibility of stopping the test at the first stage using more stringent acceptance criteria. The following are step-by-step instructions for the two-stage test.

- 1. For each position in the assembly, test one USP DPVS Prednisone RS tablet, and record the percent dissolved at the sampling time point specified. Transform the percent dissolved results to the natural log scale, determine the mean and variance.
- 2. Convert the results of Step 1 to a GM and %CV and compare to the 1st Stage of Two Stages acceptance ranges in Table 2. The GM must not fall outside the limits, and the %CV must not be greater than the limit. For calculation of the GM and %CV, see Calculation Example for details.
- 3. If results of Step 2 satisfy both acceptance criteria, the assembly has passed the PVT. Otherwise continue to Step 4. Prior to proceeding to Step 4, see Futility Factor section.
- 4. Repeat Step 1 with an additional set of tablets. Transform the percent dissolved results to the natural log scale determine the mean and variance for the data obtained at this step.
- 5. Average the two means and two variances obtained in Steps 1 and 4.
- 6. Convert the results of Step 5 to a geometric mean (GM) and percent coefficient of variation (%CV). For calculation of the GM and %CV, see Calculation Example for details.
- 7. Compare the results of Step 6 to the 2nd Stage of Two Stages acceptance ranges in Table 2. The GM must not fall outside the limits, and the %CV must not be greater than the limit. If both meet the acceptance criteria, the assembly has passed the PVT.

Table 2. Performance Verification Test Acceptance Criteria for Two-Stage Test

Apparatus	No. of	First Stage of Two-Stage Test		Second Stage of Two-Stage Test	
	vessels per run	Geometric Mean, % Prednisone Dissolved	%CV	Geometric Mean, % Prednisone Dissolved	%CV
1 (Basket)	6	80-87	3.3	77-90	4.4
	7	80-87	3.3	77-90	4.3
	8	80-87	3.3	78-90	4.2
2 (Paddle)	6	45-52	5.3	43-54	7.1
	7	45-51	5.3	43-54	6.9
	8	45-51	5.3	43-53	6.8

Copyright 2024 The United States Pharmacopeial Convention. All rights reserved. USP Reference Standard Certificate Template No.: FORM-00008-03

Page 3 of 6

ÖOÙÙÈEGĂÍ′ÚÛ′ÜGFHP€È`]



Futility Factor

If optional Stage-Two test is chosen, there are circumstances when the %CV after the First Stage of Two-Stage test equals or exceeds the value in the Futility Factor table (without rounding). In such cases it is impossible to meet the %CV criterion after the Second Stage of the Two-Stage test. The lab can stop after the First Stage run. However, after any adjustments to equipment, test procedure, and so on, the PVT must be restarted with a new first run (Step 1 of the two-stage test instructions).

Futility Factor, %CV at or above value given, second stage testing will not produce passing result

Apparatus	Number of Vessels		
	6	7	8
1	6.2	6.1	5.9
2	10	9.8	9.6

Refer to this website for the USP Calculation Tool: https://apps.usp.org/app/USPNF/pvtCalculationTool/

Calculation Example (expressed as Microsoft Excel® worksheet functions):

Run 1: x_1 , x_2 , ..., x_n in natural log scale: Ln x_1 , Ln x_2 , ..., Ln x_n

Run 2: x_{n+1} , x_{n+2} , ..., x_{2n} in natural log scale: Ln x_{n+1} , Ln x_{n+2} , ..., Ln x_{2n}

1st Stage of Two-Stage for n=6, 7, 8 and Single-Stage for n=12, 14:

GM1 = exp(average (Ln x_1 :Ln x_n))

 $CV1 = 100*sqrt(exp(var(Ln x_1:Ln x_n)) -1)$

Single-Stage or 2nd Stage of Two-Stage for n= 6, 7, 8:

 $\mathsf{GM} = \exp(\operatorname{average}(\operatorname{Ln} x_1:\operatorname{Ln} x_n)), (\operatorname{average}(\operatorname{Ln} x_{n+1}:\operatorname{Ln} x_{2n})))) = \exp(\operatorname{average}(\operatorname{Ln} x_1:\operatorname{Ln} x_{2n}))$

%CV= 100*sqrt(exp(average((var(Ln x_1 :Ln x_n)),(var(Ln x_{n+1} :Ln x_{2n})))) -1)

exp: exponential (e^x) var: variance sqrt: square root *: multiply 100: conversion factor to percentage

For more information and guidelines about how to complete the performance verification test refer to the

following website: https://www.usp.org/small-molecules/pvt



Copyright 2024 The United States Pharmacopeial Convention. All rights reserved. USP Reference Standard Certificate Template No.: FORM-00008-03

Page 4 of 6



Label



DISSOLUTION PERFORMANCE VERIFICATION STANDARD – PREDNISONE 30 Tablets

The nominal weight of prednisone in each tablet is 10 mg. At the time of use, open the aluminum sachet, remove the blister card, and push the tablets through the foil backing of the blister card. Use only whole tablets. Store at controlled room temperature. Do not refrigerate. Keep unused or unopened blister strips in the secondary package.

Danger! Causes eye irritation. Suspected of damaging fertility or the unborn child. Causes damage to organs (endocrine system) through prolonged or repeated exposure.

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dust/fume/gas/mist/vapors/spray. Wash thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection. If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. If exposed or concerned: Get medical advice/attention. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.

See certificate for any additional information.

USP, 12601 Twinbrook Pkwy, Rockville, MD, +1-301-881-0666
Cat. No. 1222818 Material mfd. in Spain

LOT: R213H0

Danielle A. Vattimo

Quality Assurance

Certificate Version History

use as a drug.

Not for

USP

For

Version Number	Date	Reasons for Change
00	04-SEP-2025	First issue

Copyright 2024 The United States Pharmacopeial Convention. All rights reserved. USP Reference Standard Certificate Template No.: FORM-00008-03

Page 5 of 6



Label

Reference Standard label typically contains the name, catalog number, lot number, package size, assigned value when applicable, storage conditions, handling instructions, and country of origin information. The label may also include hazard and precautionary statements required by the Occupational Safety and Health Administration (OSHA).

Assigned Value

For USP Reference Standards with compendial quantitative use(s), an assigned value is provided on the label and/or the Certificate.

For USP Reference Standards with compendial qualitative use(s), USP may choose to provide a value, e.g., chromatographic purity, for informational purposes in the Certificate, on a case-by-case basis.

Valid Use Date

It is the responsibility of the user to ascertain that a particular lot of a USP Reference Standard has official status either as a "Current Lot" or as a "Previous Lot" within the assigned valid use date. The online USP Reference Standards Catalog and the online USP Store at www.usp.org are updated daily. USP recommends referring to one of these sources prior to using a USP Reference Standard to make sure the lot is valid for use.

Storage

Storage conditions are lot—specific and may change from one lot to another. Storage conditions on the label and/or the Certificate are valid for unopened container as received. Once the container is opened, unless otherwise specified on the label and/or the Certificate, users are responsible for storing any remaining material according to their site procedures and ensuring continued suitability for its intended use. If no specific directions or limitations are provided on the label, conditions of storage include storage at room temperature and protection from moisture, light, freezing, and excessive heat. See General Chapter <659> in the USP-NF Online for storage and handing definitions.

Instructions for Use

Follow the instructions provided on the label and/or the Certificate and in the associated USP documentary standard(s). Please refer to General Chapter <11> for additional information.

Non-USP Compendial Use

USP Reference Standards are for use in analytical or laboratory applications generally as specified in USP compendia. They are not for use in humans or animals as drugs, food, or medical devices. It may be possible to use a USP RS outside of its associated USP compendial applications; however, it is the responsibility of the user to determine the suitability of the USP RS for a non-USP use.

LEGAL NOTICE

USP WARRANTS GOOD TITLE TO USP REFERENCE STANDARDS ON DISPATCH FROM USP. THE FOREGOING WARRANTY IS IN LIEU OF ANY OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY THAT THE PRODUCTS, INCLUDING THIS CERTIFICATE, ARE OF MERCHANTABLE QUALITY. USP'S LIABILITY ARISING OUT OF OR RELATING TO THE SUPPLY OF USP REFERENCE STANDARDS AND THIS CERTIFICATE SHALL IN NO EVENT INCLUDE LOSS OF PROFITS, COST OF PROCURING SUBSTITUTE GOODS OR SERVICES, OR ANY INCIDENTAL, INDIRECT, OR CONSEQUENTIAL DAMAGES OF ANY KIND, EVEN IF USP IS AWARE OF THE POSSIBILITY OF SUCH DAMAGES. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, USP DOES NOT WARRANT THAT THE USE OR RESALE OF USP REFERENCE STANDARDS, INCLUDING THEIR USE TO PERFORM TESTS AND ASSAYS PUBLISHED BY USP, WILL NOT INFRINGE UNITED STATES OR ANY OTHER PATENTS.

USP Reference Standards are not intended for use as drugs, food, or as medical devices.

This certificate may not be reproduced without the express written permission of USP.

Copyright 2024 The United States Pharmacopeial Convention. All rights reserved. USP Reference Standard Certificate Template No.: FORM-00008-03

Page 6 of 6

ÖQÙÙÈŒĂÍ′ÚÛ′ÜGFHP€È`]

DISSOLUTION SYSTEMS PERFORMANCE QUALIFICATION Agilent CrossLab Compliance Services





Standard PQ Test Suite

This document describes the test program for qualifying dissolution instruments, and the following tables list all PQ tests. PQ affirms that your dissolution apparatus performs in accordance with current USP requirements. The USP Dissolution Performance Verification Test (PVT) is performed as required in the current USP General Chapters, Dissolution <711> and Drug Release <724>, in accordance with cGMPs.

Note: The actual test limits are subject to change when a new prednisone standard is released. A custom EQP is available with limits for the current USP lot.

Test	Setpoints and Parameters	Limits
Standard Preparation	N/A	% Absorbtivity \geq 99.0% and \leq 101.0% for working and control standards (calculations are performed <u>only</u> if the control standard is used)
Filter Validation	N/A	Recovery $\geq 98\%$ and $\leq 102\%$ for each filtered aliquot
Prednisone Qualification (All variations of test)	Vessel temperature: 37.0°C Elapsed time: 30 minutes (target window from tablet drop to sampling)	See current USP lot's Certificate of Analysis

Consumables, Supplies, and Parts Used for Qualification

All parts, supplies, standards and consumables specified by the Agilent qualification protocol are provided by the customer. Agilent does not provide Prednisone standards due to the impact of improper storage, which can adversely affect the potency and/or purity of the standards and put the integrity of the qualification at risk. Agilent will provide equipment necessary for the measurement of physical parameters (e.g., thermometer, level, tachometer, wobble gauge, etc.). Any additional parts for maintenance or repair needed to affect qualification will be billed to customer unless otherwise covered by Agilent service and support agreement.

Test Design and Rationale

PQ service does not include physical testing (e.g., measurements of speed, wobble, centering, level, etc.). Because the physical condition of the Dissolution tester can affect the outcome of the Performance Qualification, it is recommended that an inspection of the equipment and measurements of physical parameters are performed prior to the service to ensure that the equipment conforms to pharmacopeia requirements.

Standard Preparation

Description: This test describes how to prepare standards for the PQ tests.

Procedure: Refer to prednisone certificate for details

Filter Validation

Description: This test validates the filters used for sample and standard preparation.

Procedure: This test compares absorbance readings of three filtered aliquots of working standard.

Prednisone Qualification

Description: These chemical tests verify the performance of the dissolution tester.

Procedure: Refer to prednisone certificate for details.

www.agilent.com/chem/qualification

Information, descriptions and specifications in this publication are subject to change without notice.

© Agilent Technologies, Inc. 2024 Published in USA

FYdcfhUbX'8 Y]j YfmCdh]cbg

V@# Á## of\$\^[[, Á#, &| a^-A#,] cat} • Á*^|^&c^aA*_| f#, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*_| f*, &| a*_A*

\(\text{QZ}\\\delta\text{QZ}\\\delta\text{Q}\) \(\text{Q}\\\\delta\text{A}\\\delta\text{A}\\\delta\text{A}\\\delta\text{A}\\\delta\text{A}\text{A}\\delta\text{A}\\delta\text{A}\\delta\text{A}\\delta\text{A}\text{A}\\delta\text{A}\text{A}\\delta\text{A}

ËÄÙ@Q, Á&@[{æe[*¦æe[• ËÄÙ@Q, Á@æå^¦Áæp}åÁ{[o^¦Á[}Á&[ç^¦ ËÄQ&|`å^Á^]^æe^åÁ`}Á[*• ËÄQ&|`å^Á/!æ}•æ&dā[}Á[*•

GY YWYX G][bUti fY Cdh]cbg

Ùcaeč • KÁÒÛ ÚÁ § Á, [cÁ [&\ ^ å

ËÄÜ^][¦cā]*Áçælãæ)&^Ás Ásæl[, ^åÁs Ás@à ÁÖÛÚ

7 i ghca Yf 5 ddfcj U

Þæ{ ^K

Vã¢^K

Öæe^K

Ùāt}æci'^K

Þæ{ ^K

Vã¢^K

Öæe^K

Ùāt}æcč¦^K

Þæ{ ^K

Vãd^K

Öæe^K

Ùāt}æci'^K

Þæ{ ^K

Vã¢^K

Öæe^K

Ùat}æci'^K

@[U'Bch]W/

Éܦ[å* & oÁÖ^•& lā]cā[}ÁDÁÜ]^& & aæā[ææā[} ÉŠã^ÁÔ^&|^ÁÚ@æ•^•ÁDÁV|æ;•ãā[}ÁŒ]]¦[çæ; ÉÜ * æ†aã ÁŒ••'|æ;& ^ÁDÁV^•cā]* ÉÖ[&~{^}cææā[}Áse;åÁÔ@æ;*^ÁTæ;æ*^{^}c ÉÜ[~¦&^ÁÔ[å^